For example, PPARγ agonists have been shown to decrease Aβ accumulation, either by reducing Aβ production or enhancing its clearance, thus counteracting neuroinflammation and improving memory impairments both in several AD rodent models and in humans with mild‐to‐moderate AD (Escribano et al. 2010; Govindarajulu et al. 2018). The gene discussed is PPARG; the disease is Alzheimer disease.